A series of research articles about the insulin analogue Lantus have been published recently by the European Association for the Study of Diabetes.
One of these studies in particular raised questions that the use of Lantus may be associated with an increase in cancer risk, particularly in people using Lantus as their sole source of insulin treatment.
It is important to note that all of these studies were observational in nature and involved primarily people with insulin-dependant type 2 diabetes. This means the researchers could only draw conclusions from general statistical trends and couldn’t exclude the possibility that their study results may be influenced by other factors including environment or lifestyle.
In summary, clinicians and researchers do not recommend that you stop taking Lantus on the basis of these studies but you may wish to discuss your diabetes management program with your healthcare provider.
You can find out more information at the website below or by contacting JDRF on (02) 99660400.
Alternatively, the sanofi-aventis patient information phone number is 1800 LANTUS (526887).